Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Cian Healthcare's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542678 vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cian Healthcare's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cian Healthcare Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cian Healthcare's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cian Healthcare's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cian Healthcare (BOM:542678) has a Buyback Yield % of -0.22 as of Sep. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cian Healthcare and its competitors. According to the industry distribution chart, Cian Healthcare ranks #110 out of 234 companies in the Drug Manufacturers industry, placing it in the top 47%.
Is Cian Healthcare's Buyback Yield % too high?
Cian Healthcare's current Buyback Yield % is -0.22. Based on the distribution chart, Cian Healthcare ranks #110 out of 234 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cian Healthcare has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cian Healthcare's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cian Healthcare ranks #110 out of 234 companies for Buyback Yield %. This puts Cian Healthcare in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cian Healthcare and its competitors. Cian Healthcare's current Buyback Yield % is -0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cian Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Cian Healthcare (BOM:542678) is currently considered Possible Value Trap. The stock's GF Value™ is ₹81.26, compared to a current price of ₹12.16 — trading 85% below its estimated fair value. The current Buyback Yield % is -0.22. Cian Healthcare's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cian Healthcare (BOM:542678), the current Buyback Yield % is -0.22 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cian Healthcare (BOM:542678) Overvalued in 2026?
Based on GuruFocus' analysis, Cian Healthcare stock appears to be undervalued.
The current stock price of ₹12.16 is trading 85% below its estimated GF Value™ of ₹81.26.
GuruFocus considers Cian Healthcare to be Possible Value Trap.
Key valuation signals for BOM:542678:
Buyback Yield %: -0.22
GF Value™: ₹81.26 vs. price of ₹12.16 (85% below fair value)
No single metric tells the full story. See the BOM:542678 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cian Healthcare Ltd is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company manufactures multiple product lines, including tablets, capsules, soft gels, liquid orals, ointments/creams and sachets, and cosmetics. Its portfolio comprises gynecology, haematinic, cardio-diabetic, orthopedic, pediatric, dermacosmetic, antibiotic, CNS, vitamins, and nutrient products. The company operates in five sectors: Export, Government Supplies, Merchant Export, Own Brand Franchise Business, and Third Party/Contract Manufacturing.
50GF Score
Get the complete analysis for BOM:542678
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542678 has been successfully added to your 
